

Nov 2022

The National Centre for Infections and Cancer. NHMRC CRE App # 1116876, NHMRC Synergy grant#2011100

•••

NCIC Report

Nov 2022

Preamble:

There is compelling evidence that infection in cancer patients remains a leading cause of death and a significant cost to the healthcare system. No group is systemically addressing this problem in Australia nor is it addressed in national cancer strategies.

This Synergy program aims to:

1. Establish a national infrastructure for cancer specific infection surveillance.

2. Nationally implement life saving and harm minimising clinical care pathways.

3. Introduce innovative technologies to support the detection of and improve care of infections.

4. Build workforce capacity in infections and cancer

Purpose:


The purpose of this report is to provide feedback on Synergy activities to date and to outline progress towards sustainability.



The National Centre for Infections in Cancer was conceived in response to data on infections in cancer being a leading cause of death and a significant cost to the healthcare system.

To date, no group has systematically addressed this problem in Australia nor is it addressed in national cancer strategies.

Centre Structure	3
Funding report	3
Commonwealth funding for cancer and infection projects	3
Industry funding for cancer and infection projects	ł
Track record	5
Publications	5
Public engagement	5
Seminars, conferences and education programs	5
Progress towards sustainability	5
Infection surveillance	5
Implementation of clinical care pathways	7
Innovative technologies	3
Workforce capacity	3
References)



Centre manager: Dr Megan Crane

Clinical trials team: Rachel Woolstencroft, Gwyn Ng, Marcel Stewart, Hayley Page, Jess Demajo, Chhay Lim, Jenny Gallagher, Surekha Tennakoon, Natalie Saunders, Emily Klimevski, Beatrice Sim, Nick Laundy PhD students: Victoria Hall, Gemma Reynolds, Jasmine Teng, Alison Lemoh, Dan Neoh

Funding report

Commonwealth funding for cancer and infection projects

NCIC began in 2017 with \$2.5 million in funding as an NHMRC Centre for research Excellence. In Jan 2022 the NCIC was awarded a further \$5 million NHMRC synergy grant until 2026. Since beginning in 2017 we have secured a total of \$20 million in NHMRC and MRFF grants for projects in infections in cancer.

Table 1 (Lead investigator funding)

Investigator	Year	Study/Project	Source	Funding
Monica Slavin	2017	NCIC	NHMRC	\$2.5 million
	2019	Investigator	NHMRC	\$1.6 million
	2020	CSMART	MRFF	\$2.169 million
	2022	Synergy	NHMRC	\$5 million
Karin Thursky	2016	PICNICC	NHMRC	\$600,000
	2017	No place like home	BCV	\$445,000
	2019	AFS	NHMRC	\$1.6 million
	2022	Appropriate Antimicrobial Use	MRFF	\$3 million
Gab Haeusler	2019	No place like home	MRFF	\$1.2 million

• • •

Ben Teh	2021	Investigator grant	MRFF	\$1.1 million
	2022	Foundation grant	PMCC	\$50,000
Jason Trubiano	2018	Allergy	BCV	\$400,000
Abby Douglas	2022	Foundation grant	PMCC	\$50,000
				\$19.714 million

In addition NCIC investigators have been named on and receive funding through our network collaborations.

Table 2 (Non lead funding)

Year	Study/Project	Lead Investigator	Source	Funding total
2022	Immune responses to COVID	Katherine Kedierska (UoM)	MRFF	\$3 million
2021	META-GP	Deborah Williamson (RMH)	NHMRC	\$7 million
2021	Super bugs II	Lindsay Grayson (Austin health)	NHMRC	\$2 million
2021	CRE-Respond	Jason Roberts (UQ)	NHMRC	\$2.5 million
2021	C-FIND	Marc Pellegrini (WEHI)	MRFF	\$870,000

Industry funding for cancer and infection projects

Since establishing the NCIC clinical trials team in 2017 we have worked on a number of investigator initiated and pharma initiated clinical trials. The Clinical trials team of 4 research nurses (Gwyn Ng, Haley Page, Marcelle Stewart and Jess Demajo) a data manager (Belinda De Poi), 2 clinical trials assistants (Chhay Lim and Jenny Gallagher) and 3 laboratory assistants (Surekha Tennakoon, Natalie Saunders and Emily Klimevski) is led by nurse manager Rachel Woolstencroft and medical lead Dr Michelle Yong.

Table 3 (Investigator initiated and pharma initiated clinical trials)

Investigator	Year	Study/Project	Source	Funding
Monica Slavin	2018	F2G	F2G	\$70,000/patient
	2019	Paraflu	Ansun	\$45,000/patient
	2018	Restore	Cidara	\$70,000/patient
	2020	APX001	Medpace	\$50,000/patient
	2020	SYNERGIA	Syneos	\$50,000/patient
	2019	Posa	MSD	\$120,000
	2020	RSV	Janssen	\$50,000/patient

• • •

Ben Teh	2019	Flu vax I	MSD	\$60,000
	2022	Flu vax II	Sanofi	\$50,000
	2021	PROSECCO	Merck	\$100,000
Michelle Yong	2018	Cresct	MSD	\$270,000
	2020	Cresct expansion	MSD	\$250,000
	2022	Paxlovid	Pfizer	\$123,000/pt
Abby Douglas	2019	PIPPIN	Gilead	\$60,000
Shio Yen	2020	CrispBAL	Gilead	\$60,000
Zoe Neoh	2020	Auslopro	F2G	\$300,000
	2022	Fungal surveillance	Gilead	\$60,000

Track record

Publications Time period: Jan 2017- Jun 2022

- Total 1219 papers, 1547 citations
- Average 12.3 citations per paper
- 41.5% are due to an international collaboration, 56.8% are a national collaboration
- Average Field weighted citation impact factor 1.94
- 36.2% in top 10% journals
- 69.1% are in the field of Medicine, also publish in fields of Immunology, Biochemistry and Pharmacology

Public engagement

Table 4

Туре	Analytics
Website	2017: 737 unique visitors, 2,165 page views
	2019: 2384 unique visitors, 4498 page views
	2020: 6900 unique visitors, 12000 page views
Twitter (28 day snapshot)	2017: 13.1K impressions
	2019: 14.1K impressions
	2020:15.5K impressions
Features	4x MJA articles on microbiome
	1x Conversation article on Candida Auris

• • •

ABC news interview Candid Auris 1X conversation article on Mucor Mycosis and COVID
BBC World news interview Mucor Mycosis and COVID

Seminars, conferences and education programs Table 5

Туре	Year	Торіс
Conference	2021	International Conference of the Immunocompromised Host Society (ICHS)
Symposium	2017	NCIC Launch
	2018	What's new in cancer
	2019	New Frontiers in cancer infection management
	2020	Fungal infections in focus
	2022	COVID in ICH
Forum	2019	Your gut Health: consumer engagement
	2022	Synergy IM
	2022	PROSECCO IM
Invited speakers	2017	Peter Pappas: C.Diff, Paul Verweij: antifungals
	2018	Josh Hill: ICIs and HSV, Jason Roberts: PK/PD
	2019	Bob Finberg: Flu, Burton Dickie: novel antivirals, Dena Lyras: FMTs
Medical and nursing in- service education	Ongoing	Sepsis pathway in service
	Ongoing	ID for Haem- registrar training

Progress towards sustainability

Infection surveillance

- The NCIC has demonstrated the significant burden of infections using manual surveillance methods [1].
- We have successfully piloted the use of large linked datasets to reduce resource demands of reporting [2].
- We have led the concept of enhanced surveillance for cancer-related infections (sepsis, invasive fungal infections, blood stream infections, and *Clostridiodes difficile*) using gold-standard data linked to administrative data [3-5]

• • •

- We have a proof-of-principal project (Antifungal Stewardship) under development in a current NHMRC project grant (AFS-see table 1)
- We are currently carrying out a national surveillance for fungal infections (AusLoPro- see table 3)

Implementation of clinical care pathways

Table 6

Pathway	Innovation	Economic savings	Patient outcomes
Cancer Sepsis Pathway [6, 7]	First ever whole of hospital nurse led clinical pathway for recognition and management of sepsis (single site)	Short term ICER of \$8000 per patient on pathway with lives saved. Future costing across cancer types cost effectiveness[8]	Reduction in mortality ~50%, LOS, ICU admission
Think Sepsis Act Fast Scaling Collaboration [9]	Cancer sepsis pathway adapted for non cancer hospitals, and implemented in 24 Victorian hospitals	\$11.5 million cost savings for the project Short term ICER cost saving and more effective	Reduction in mortality ~50%, LOS, ICU admission adjusted for sepsis severity
Ambulatory pathway of care for low risk neutropenic fever in adults and children	First adult and paediatric low risk FN program. Paed program scaled nationally 8 sites and internationally to 12 sites[10]	Paed: mean cost saving \$12,800 per patient on programAdults: Health economic model projected	Improved QoL, reduction in LOS, increased bed access and no adverse outcomes.
Vaccination pathways for high risk patients [11]	Vaccination protocol and counselling service for patients at high risk for vaccine- preventable infections (3 sites)	For evaluation	Near universal vaccination uptake and higher completion rates
Point-of-care Antibiotic Allergy delabelling [12]	First ever inpatient and outpatient AMS led delabelling program for antimicrobials. In 2 sites: Peter Mac and Austin hospitals	\$335 per patient cost saving was noted in a cost-effectiveness analysis with an inpatient penicillin delabelling program.	10-fold increase in narrow spectrum penicillin usage, 2-fold increase in appropriate prescribing

ICER; incremental cost effectiveness ratio, LOS, length of stay; ICU, intensive care; QoL, quality of life, FN Febrile neutropenia

Innovative technologies

NCIC has established a highly successful Clinical trials group which employs four clinical trials nurses, two clinical trials assistants and two laboratory research assistants. Current pharma and investigator initiated trials (table 3) in cancer patients include:

- Novel antifungals (F2G, Restore, APX001, Synergia),
- Novel antivirals (RSV, paraflu),
- Novel prophylaxis strategies (Flu vax, CSMART {see table 1}, posa)
- Novel diagnostics (Pippin, CrispBAL, Cresct and Cresct expansion)

Workforce capacity

- NCIC employs 31 people on both clinical, trials and research roles (Table 7)
- NCIC has 7 current and 5 completed PhD students (Table 8)

Ta	b	le	7

	Dele
Staff member	Role
Monica Slavin	Dept head, stream lead, clinician
Karin Thursky	Dept head, stream lead, clinician
Leon Worth	Dept head, stream lead, clinician
Ben Teh	Fellow, clinician
Michelle Yong	Fellow, clinician
Belinda Lambros	Nurse Practitioner
Registrar	Clinician
Gab Haeusler	Fellow, clinician
Jason Trubiano	Fellow, clinician
Abby Douglas	PhD student, clinician
Shio Yen Tio	PhD student, clinician
Su Ann Ho	PhD student, clinician
Olivia Smibert	PhD student, clinician
Morgan Rose	PhD student, clinician
Megan Crane	Manager
Krishna Brannigan	Admin
Nick Laundy	International visiting fellow
Chhay Lim	Research Assistant
Marcelle Stewart	Research nurse
Surekha Tennakoon	Research Assistant
Natalie Saunders	Research Assistant
Rachel Woolstencroft	Research nurse
Hayley Page	Research nurse
Gwyn Ng	Research nurse
Anna Khanina	Fellow
Zoe Neoh	Fellow

•••

Jenny Gallagher	Research Assistant
Belinda Depoi	Data manager
Jess DeMajo	Research nurse
Victoria Hall	PhD student, clinician
Gemma Reynolds	PhD student, clinician

Table 8 PhD students

Student	Completion year	Scholarship
Abby Douglas*	2021	UoM
Shio Yen Tio	2023	NHMRC
Su Ann Ho	2023	CRE-REDUCE
Michelle Tew*	2020	UoM
Jake Valentine*	2021	UoM
Oliva Smibert**	2023	NHMRC
Victoria Hall	2024	NHMRC
Gemma Reynolds	2024	NHMRC
Jasmine Teng	2024	NHMRC
Julian Lindsay*	2021	NCIC
Brendan McMullen*	2020	UoM
Morgan Rose	2023	UoM
Dan Yeoh	2022	UoM
*Completed		

*Completed

**Recipient of the Gus Nossal NHMRC PhD fellowship and The Rosie Lew PMCC PhD fellowship awards

- In 2020 we appointed an AMS Nurse Practitioner (Belinda Lambros)
- Current research fellows have won numerous awards, are now Head of Department and/or are named as CIA on grants (Table 9)

Table 9 Career Development awards

Investigator	Year	Award/achievement
Ben Teh	2018	UoM Chancellors Award
	2018	Vic Premier's award
	2020	NHMRC Investigator grant
	2021	Appointed Advisor to ATAGI
Gab Haeusler	2018	Vic Premier's award
	2019	UoM Chancellors Award

• • •

	2019	CIA on MRFF project grant
Jason Trubiano	2020	Appointed Acting Head Dept ID Austin Hospital
Karin Thursky	2019	FAAHMS
	2019	UoM Kay Campbell Fellowship
	2021	Assoc, Director HSRIS
Monica Slavin	2019	FAAHMS
	2021	UoM Chair ICH
Michelle Yong	2022	PMCC Women in Science Lea medal
Abby Douglas	2022	PMCC Significant PhD award

References

- 1. Valentine, J.C., et al., *Use of a Victorian statewide surveillance program to evaluate the burden of healthcare-associated Staphylococcus aureus bacteraemia and Clostridioides difficile infection in patients with cancer.* Intern Med J, 2021.
- 2. Valentine, J.C., et al., *Classification performance of administrative coding data for detection of invasive fungal infection in paediatric cancer patients.* PLoS One, 2020. **15**(9): p. e0238889.
- Valentine, J.C., et al., Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. Support Care Cancer, 2020. 28(12): p. 6023-6034.
- 4. Valentine, J.C., et al., *Sepsis incidence and mortality are underestimated in Australian intensive care unit administrative data*. Med J Aust, 2019. **210**(4): p. 188-188 e1.
- 5. Valentine, J.C., et al., *The current scope of healthcare-associated infection surveillance activities in hospitalized immunocompromised patients: a systematic review.* Int J Epidemiol, 2019. **48**(6): p. 1768-1782.
- 6. Thursky, K., et al., *Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs.* BMJ Open Qual, 2018. **7**(3): p. e000355.
- Hiong, A., et al., *Impact of a hospital-wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre*. Eur J Cancer Care (Engl), 2019. 28(3): p. e13018.
- 8. Tew, M., et al., *Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.* Pharmacoeconomics, 2019. **37**(7): p. 931-941.
- 9. *Think Sepsis Act Fast Evaluation Report. Safer Care Victoria,* 2019 Available from: <u>https://www.bettersafercare.vic.gov.au/improvement/projects/mtip/think-sepsis-act-fast.</u>
- 10. Phillips, B. *York AC*. Available from: <u>https://www.york.ac.uk/research/coronavirus-</u> research/applied-health/shortening-hospital-stays-child-cancer.
- 11. Teh, B.W., et al., *Impact of a dedicated post-transplant vaccination service at an Australian cancer centre*. Bone Marrow Transplant, 2017. **52**(12): p. 1681-1683.
- 12. Trubiano, J.A., et al., *The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients*. Antimicrob Resist Infect Control, 2015. 4: p. 23.